All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
FDA expands indication of Vonvendi to include children with VWD
The approval now includes on-demand and perioperative bleeding management in paediatric patients, along with prophylaxis for adults with VWD.
Phoenix, MD Anderson partner to advance cell and gene therapies
Phoenix will receive a supply of rimiducid from MD Anderson and support for regulatory approval of a new injectable formulation.
MRM Health secures €55m to advance microbiome-based therapeutics
MRM Health will use the funds to support a Phase 2b trial of its lead asset, MH002, in treating mild-to-moderate ulcerative colitis.
Lilly gains FDA breakthrough status for olomorasib in advanced lung cancer
The olomorasib combination is intended for treating advanced NSCLC with KRAS G12C mutations and high PD-L1 expression.
Gilead begins construction of new manufacturing centre in US
The move is part of the company’s $32bn investment strategy in US innovation through 2030, aimed at generating over $43bn in economic value.
Argo, Novartis expand collaboration for cardiovascular therapies
The expanded partnership includes licensing and option agreements for cardiovascular assets in Argo’s portfolio, focusing on siRNA therapeutics.
Amgen to invest over $600m in new science and innovation centre
The initiative aims to strengthen collaboration among researchers, engineers, and scientists to expedite the discovery of new therapeutics for severe diseases.
Arrowhead Pharma, Novartis enter licensing deal for siRNA therapy
Arrowhead Pharma will receive an upfront payment of $200m and is eligible to earn up to $2bn in milestone payments, alongside royalties on future sales.
Sanofi secures FDA approval for Wayrilz to treat chronic ITP
Wayrilz is an oral BTK inhibitor that works by modulating immune responses to address the underlying causes of ITP.
Boehringer Ingelheim gets approval for Hernexeos in China for HER2-mutant NSCLC
Hernexeos is indicated for adults with unresectable, locally advanced, or metastatic NSCLC with activating HER2 mutations, after at least one line of prior therapy.